 Pharmacogenomic studies will be largely exploratory and will consist of TaqMan SNP genotype assays for genotyping single nucleotide polymorphisms SNPs annotated in UGT1A6, ABCB4, ABCC1, HNMT, SLC28A3, FMO2, SPG7, SLC10A2, SLC28A3 using germline DNA samples from the patients. In addition, we will employ next generation sequencing NGS approach using the TruSight One Sequencing Panel based on the Nextera Enrichment DNA Sample Prep kit Illumina, San Diego, CA which targets 4,813 genes at a 100X average coverage, and at 20X minimum coverage of 95 regions in the panel. This targeted enrichment approach will focus on genes such as, but not limited to HAS3, CBR1, CBR2, involved in cardiotoxicity, as well genes coding for proteins involved in heart cytoskeleton and metabolism. Other high-throughput approaches may also be used. 